Modality
Gene Therapy
MOA
CAR-T BCMA
Target
CDK4/6
Pathway
mTOR
NBAMLGIST
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Dec 2031
Phase 1Current
NCT05624515
434 pts·GIST
2018-02→2031-12·Recruiting
434 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-285.7y awayInterim· GIST
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2031-12-28 · 5.7y away
GIST
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05624515 | Phase 1 | GIST | Recruiting | 434 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |